Student Edition   Industry Edition  
 
Dia-B Tech rocket on insulin based patent

Shares in Dia-B Tech Limited (DIA), rocketed almost 90% on Tuesday after the group, which specialises in biotech research towards a new drug for diabetes, advised that it is filing a new provisional patent to cover a discovery in approaches to treatment of diabetes. The patent covers a mechanism whereby insulin in its native complex state is dispersed more rapidly to make a much more efficient “fast-acting” form of the single molecule in the treatment of diabetes.

Insulin forms into groups of 6 insulin molecules (hexamers) that are held together (or stabilised) by Zinc. However, only single insulin molecules (monomers) bind to insulin receptors in the body.

What Dia-B has discovered is a new combination in which hexamers of unmodified (ie natural) insulin are rapidly dispersed, so making “fast-acting” compositions of natural insulin for the treatment of diabetes.

(http://www.egoli.com.au)

 
Archives | Current News

© Amity Edumedia. All Rights Reserved.
Powered By AKC Data Systems (India) Pvt. Ltd.
Private Policy | Disclaimer